Digital healthcare provider Thirty Madison has secured $47m in series B funding from investors including medical group Johnson & Johnson’s corporate venturing unit, Johnson & Johnson Innovation – JJDC.
Healthcare technology investment firm Polaris Partners led the round, which also featured venture capital firms Maveron and Northzone. Amy Schulman, managing partner at Polaris, will take a board seat at the company in conjunction with the round.
Thirty Madison runs a digital health service that combines online consultations, home delivery for medical treatments and online support.
The company launched its first product, hair loss product Keeps, in early 2018 and followed it with migraine treatment Cove in January 2019 and acid reflux medication Evens in September.
Steven Gutentag, Thirty Madison’s co-founder and chief executive, said: “We are excited to have JJDC as an investor, given Johnson & Johnson’s leadership across healthcare and consumer health, and their commitment to putting consumers and patients first.”
Maveron, First Round Capital, Greycroft Partners and Imaginary Ventures had provided $7.5m in seed funding for the company in 2017.
The first three returned for a $15.3m series A round in October 2018 that was co-led by Maveron and Northzone and also backed by Steadfast Venture Capital, ERA, HillCour and Two River.
